Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 363.73M P/E - EPS this Y 73.20% Ern Qtrly Grth -
Income -587M Forward P/E -36.05 EPS next Y 279.00% 50D Avg Chg -9.00%
Sales 1.1B PEG 0.17 EPS past 5Y 17.06% 200D Avg Chg -37.00%
Dividend N/A Price/Book 0.30 EPS next 5Y -25.30% 52W High Chg -78.00%
Recommedations 3.00 Quick Ratio 0.43 Shares Outstanding 52.91M 52W Low Chg 7.00%
Insider Own 2.13% ROA -6.42% Shares Float 51.88M Beta 1.59
Inst Own 57.55% ROE -87.44% Shares Shorted/Prior 4.47M/3.46M Price 7.21
Gross Margin 19.82% Profit Margin -53.26% Avg. Volume 1,447,854 Target Price 8.00
Oper. Margin -62.47% Earnings Date Nov 6 Volume 1,511,597 Change -8.85%
About Emergent Biosolutions, Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent Biosolutions, Inc. News
12/16/24 Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
12/03/24 Why Emergent BioSciences Stock Plummeted Today
11/09/24 Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/08/24 Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
11/07/24 Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
11/07/24 New Strong Buy Stocks for November 7th
11/07/24 Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
11/06/24 Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
11/06/24 Emergent Biosolutions: Q3 Earnings Snapshot
11/06/24 Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
11/06/24 Emergent BioSolutions Reports Third Quarter 2024 Financial Results
11/04/24 Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
10/28/24 Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store
08:42 AM 5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades
10/23/24 Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
10/15/24 Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata
10/14/24 3 Stocks Poised for Better Returns With New Analyst Coverage
10/11/24 Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024
10/09/24 Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...
10/09/24 Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zoon Kathryn C Director Director May 25 Sell 8.37 3,530 29,546 49,971 07/24/23
Richard Ronald Director Director Nov 25 Sell 11.94 1,912 22,829 19,837 11/29/22
Havey Adam EVP, Business Operat.. EVP, Business Operations Mar 03 Option 40.14 37,279 1,496,379 58,335 03/03/21
Havey Adam EVP, Business Operat.. EVP, Business Operations Mar 03 Sell 99.32 37,279 3,702,550 38,190 03/03/21
Kramer Robert President and CEO President and CEO Feb 09 Option 30.75 45,397 1,395,958 152,210 02/09/21
Kramer Robert President and CEO President and CEO Feb 09 Sell 120.03 45,397 5,449,002 139,210 02/09/21
Kramer Robert President and CEO President and CEO Jan 19 Option 25.62 19,026 487,446 158,236 01/19/21
Kramer Robert President and CEO President and CEO Jan 19 Sell 106.01 19,026 2,016,946 139,210 01/19/21
El-Hibri Fuad Chairman Chairman Nov 12 Option 26.45 39,391 1,041,892 1,143,379 11/12/20
El-Hibri Fuad Chairman Chairman Nov 12 Sell 91.74 39,391 3,613,730 1,123,988 11/12/20
El-Hibri Fuad Chairman Chairman Nov 04 Option 26.45 40,000 1,058,000 1,143,988 11/04/20
El-Hibri Fuad Chairman Chairman Nov 04 Sell 90.59 40,000 3,623,600 1,123,988 11/04/20
El-Hibri Fuad Chairman Chairman Sep 25 Sell 99.72 25,535 2,546,350 1,123,988 09/25/20
El-Hibri Fuad Chairman Chairman Sep 18 Sell 101.58 40,000 4,063,200 1,149,523 09/18/20
El-Hibri Fuad Chairman Chairman Sep 11 Sell 102.73 40,000 4,109,200 1,189,523 09/11/20
SULLIVAN LOUIS W Director Director Sep 04 Option 20.08 7,893 158,491 50,655 09/04/20
SULLIVAN LOUIS W Director Director Sep 04 Sell 111.22 28,418 3,160,650 42,762 09/04/20